Ironwood Swings For The IPO Fences
This article was originally published in The Pink Sheet Daily
Executive Summary
The developer of a Phase III constipation drug wants to raise nearly $270 million in the first week of February. Will it hit a financing home run or strike out?
You may also be interested in...
Is Ironwood The IPO Medicine To Get Things Moving?
Ironwood Pharmaceuticals' $188 million IPO was like the proverbial elephant among the blind men. How you perceived it depended upon where you touched it
Is Ironwood The IPO Medicine To Get Things Moving?
Ironwood Pharmaceuticals' $188 million IPO was like the proverbial elephant among the blind men. How you perceived it depended upon where you touched it
Ironwood IPO Raises Plenty Of Cash And Plenty Of Questions For Biotech Investors
The much-anticipated debut of the constipation-drug developer hits $188 million, but a venture owner had to buy nearly half the issue.